Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'

Clin Exp Dermatol. 2023 Jun 5;48(6):701-703. doi: 10.1093/ced/llad082.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adalimumab / therapeutic use
  • Biosimilar Pharmaceuticals* / adverse effects
  • Hidradenitis Suppurativa* / chemically induced
  • Hidradenitis Suppurativa* / complications
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Mevalonate Kinase Deficiency*
  • Psoriasis* / chemically induced
  • Psoriasis* / complications
  • Psoriasis* / drug therapy
  • Ustekinumab / adverse effects

Substances

  • Adalimumab
  • Ustekinumab
  • guselkumab
  • Biosimilar Pharmaceuticals